Terms: = Prostate cancer AND EZH2, ENX-1, 2146, ENSG00000106462, Q15910, MGC9169
360 results:
1. MiR26a reverses enzalutamide resistance in a bone-tumor targeted system with an enhanced effect on bone metastatic CRPC.
Wang Y; Chen J; Gong L; Wang Y; Siltari A; Lou YR; Murtola TJ; Gao S; Gao Y
J Nanobiotechnology; 2024 Apr; 22(1):145. PubMed ID: 38566211
[TBL] [Abstract] [Full Text] [Related]
2. Race-specific coregulatory and transcriptomic profiles associated with DNA methylation and androgen receptor in prostate cancer.
Ramakrishnan S; Cortes-Gomez E; Athans SR; Attwood KM; Rosario SR; Kim SJ; Mager DE; Isenhart EG; Hu Q; Wang J; Woloszynska A
Genome Med; 2024 Apr; 16(1):52. PubMed ID: 38566104
[TBL] [Abstract] [Full Text] [Related]
3. Nuclear medicine practice in Japan: a report of the ninth nationwide survey in 2022.
Okizaki A; Nishiyama Y; Inui Y; Otsuka H; Takanami K; Nakajo M; Nakatani K; Nogami M; Hirata K; Maeda Y; Yoshimura M; Wakabayashi H
Ann Nucl Med; 2024 Apr; 38(4):315-327. PubMed ID: 38421515
[TBL] [Abstract] [Full Text] [Related]
4. Splicing targeting drugs highlight intron retention as an actionable vulnerability in advanced prostate cancer.
Naro C; Antonioni A; Medici V; Caggiano C; Jolly A; de la Grange P; Bielli P; Paronetto MP; Sette C
J Exp Clin Cancer Res; 2024 Feb; 43(1):58. PubMed ID: 38413979
[TBL] [Abstract] [Full Text] [Related]
5. ezh2-mediated development of therapeutic resistance in cancer.
Kaur P; Shankar E; Gupta S
Cancer Lett; 2024 Apr; 586():216706. PubMed ID: 38331087
[TBL] [Abstract] [Full Text] [Related]
6. A novel exosome based therapeutic intervention against neuroendocrine prostate cancer.
Saini S; Sreekumar A; Nathani S; Asante DM; Simmons MN
Sci Rep; 2024 Feb; 14(1):2816. PubMed ID: 38307935
[TBL] [Abstract] [Full Text] [Related]
7. Discovery of a novel, highly potent ezh2 PROTAC degrader for targeting non-canonical oncogenic functions of ezh2.
Velez J; Dale B; Park KS; Kaniskan HÜ; Yu X; Jin J
Eur J Med Chem; 2024 Mar; 267():116154. PubMed ID: 38295690
[TBL] [Abstract] [Full Text] [Related]
8. DPYSL5 is highly expressed in treatment-induced neuroendocrine prostate cancer and promotes lineage plasticity via ezh2/PRC2.
Kaarijärvi R; Kaljunen H; Nappi L; Fazli L; Kung SHY; Hartikainen JM; Paakinaho V; Capra J; Rilla K; Malinen M; Mäkinen PI; Ylä-Herttuala S; Zoubeidi A; Wang Y; Gleave ME; Hiltunen M; Ketola K
Commun Biol; 2024 Jan; 7(1):108. PubMed ID: 38238517
[TBL] [Abstract] [Full Text] [Related]
9. Treatment-related Neuroendocrine prostate Carcinoma-Diagnostic and Molecular Correlates.
Gopalan A
Adv Anat Pathol; 2024 Mar; 31(2):70-79. PubMed ID: 38223983
[TBL] [Abstract] [Full Text] [Related]
10. miR-26a-5p restoration
Zhang W; Nie Q; Zhang X; Huang L; Pang G; Chu J; Yuan X
Expert Opin Ther Targets; 2023; 27(12):1285-1297. PubMed ID: 38155599
[TBL] [Abstract] [Full Text] [Related]
11. ezh2 as a potential therapeutic target for gastrointestinal cancers.
Hashemi M; Nazdari N; Gholamiyan G; Paskeh MDA; Jafari AM; Nemati F; Khodaei E; Abyari G; Behdadfar N; Raei B; Raesi R; Nabavi N; Hu P; Rashidi M; Taheriazam A; Entezari M
Pathol Res Pract; 2024 Jan; 253():154988. PubMed ID: 38118215
[TBL] [Abstract] [Full Text] [Related]
12. Conformationally constrained potent inhibitors for enhancer of zeste homolog 2 (ezh2).
Xu X; Chen J; Wang G; Zhang X; Li Q; Zhou X; Guo F; Li M
Bioorg Med Chem Lett; 2024 Jan; 97():129558. PubMed ID: 37956762
[TBL] [Abstract] [Full Text] [Related]
13. Effect of BMI and hemoglobin A1c on survival of veterans with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
Govindan S; Cheranda N; Riekhof F; Luo S; Schoen MW
Prostate; 2024 Feb; 84(3):245-253. PubMed ID: 37909677
[TBL] [Abstract] [Full Text] [Related]
14.
Boldrini L; Bardi M
Genes (Basel); 2023 Jul; 14(8):. PubMed ID: 37628609
[TBL] [Abstract] [Full Text] [Related]
15. LncRNA SNHG4 promotes prostate cancer cell survival and resistance to enzalutamide through a let-7a/RREB1 positive feedback loop and a ceRNA network.
Dong Q; Qiu H; Piao C; Li Z; Cui X
J Exp Clin Cancer Res; 2023 Aug; 42(1):209. PubMed ID: 37596700
[TBL] [Abstract] [Full Text] [Related]
16. Downregulation of ezh2 inhibits epithelial-mesenchymal transition in enzalutamide-resistant prostate cancer.
Zhang Z; Wang X; Kim M; He D; Wang C; Fong KW; Liu X
Prostate; 2023 Nov; 83(15):1458-1469. PubMed ID: 37475584
[TBL] [Abstract] [Full Text] [Related]
17. Nicardipine is a putative EED inhibitor and has high selectivity and potency against chemoresistant prostate cancer in preclinical models.
Li X; Chen Y; Bai L; Zhao R; Wu Y; Xie ZR; Wu JM; Bowen NJ; Danaher A; Cook N; Li D; Qui M; Du Y; Fu H; Osunkoya AO; Kucuk O; Wu D
Br J Cancer; 2023 Sep; 129(5):884-894. PubMed ID: 37474721
[TBL] [Abstract] [Full Text] [Related]
18. Lineage plasticity and treatment resistance in prostate cancer: the intersection of genetics, epigenetics, and evolution.
Imamura J; Ganguly S; Muskara A; Liao RS; Nguyen JK; Weight C; Wee CE; Gupta S; Mian OY
Front Endocrinol (Lausanne); 2023; 14():1191311. PubMed ID: 37455903
[TBL] [Abstract] [Full Text] [Related]
19. Combining ezh2 and HDAC inhibitors to target castration-resistant prostate cancers.
Coulter JB; Easwaran H
PLoS Biol; 2023 Apr; 21(4):e3002081. PubMed ID: 37104249
[TBL] [Abstract] [Full Text] [Related]
20. Combating castration-resistant prostate cancer by co-targeting the epigenetic regulators ezh2 and HDAC.
Schade AE; Kuzmickas R; Rodriguez CL; Mattioli K; Enos M; Gardner A; Cichowski K
PLoS Biol; 2023 Apr; 21(4):e3002038. PubMed ID: 37104245
[TBL] [Abstract] [Full Text] [Related]
[Next]